Ontology highlight
ABSTRACT:
SUBMITTER: Iams WT
PROVIDER: S-EPMC5242382 | biostudies-literature | 2015 Sep-Oct
REPOSITORIES: biostudies-literature
Cancer journal (Sudbury, Mass.) 20150901 5
The therapeutic targeting of anaplastic lymphoma kinase (ALK) has been a burgeoning area of research since 2007 when ALK fusions were initially identified in patients with non-small cell lung cancer. The field has rapidly progressed through development of the first-generation ALK inhibitor, crizotinib, to an understanding of mechanisms of acquired resistance to crizotinib and is currently witnessing an explosion in the development of next-generation ALK inhibitors such as ceritinib, alectinib, P ...[more]